Gland Pharma Profile
Key Indicators
- Authorised Capital ₹ 56.30 Cr
as on 25-12-2024
- Paid Up Capital ₹ 16.48 Cr
as on 25-12-2024
- Company Age 46 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 566.83 Cr
as on 25-12-2024
- Revenue 28.55%
(FY 2022)
- Profit 21.58%
(FY 2022)
- Ebitda 16.00%
(FY 2022)
- Net Worth 21.26%
(FY 2022)
- Total Assets 20.60%
(FY 2022)
About Gland Pharma
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 543245 and on the National Stock Exchange(NSE) under GLAND.
The Corporate was formerly known as Gland Pharma Pvt Ltd. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 56.30 Cr and a paid-up capital of Rs 16.48 Cr.
The company has closed loans amounting to ₹566.83 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Gland Pharma Ltd India are Ravi Mitra as Cfo, Srinivas Sadu as Ceo, and Sampath Pallerlamudi as Company Secretary. Naina Kidwai, Satyanarayana Chavali, Essaji Vahanvati, and Five other members serve as directors at the Company.
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Gland Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ravi Mitra | CFO | 30-Sep-2019 | Current |
Srinivas Sadu  | CEO | 25-Apr-2019 | Current |
| Sampath Pallerlamudi | Company Secretary | 17-Dec-2013 | Current |
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Naina Kidwai | Director | 17-May-2021 | Current |
| Essaji Vahanvati | Director | 30-Sep-2020 | Current |
| Satyanarayana Chavali | Director | 20-Nov-2018 | Current |
Udo Vetter  | Director | 07-Feb-2018 | Current |
| Srinivas Sadu | Director and Ceo | 25-Apr-2019 | Current |
Jia Zhang  | Director | 17-May-2021 | Current |
Financial Performance of Gland Pharma.
Gland Pharma Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 28.55% increase. The company also saw a substantial improvement in profitability, with a 21.58% increase in profit. The company's net worth Soared by an impressive increase of 21.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gland Pharma?
In 2023, Gland Pharma had a promoter holding of 57.86% and a public holding of 42.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Satyarx Pharma Innovations Private LimitedActive 4 years 5 monthsSatyanarayana Chavali is a mutual person
Charges (Loans)
₹0
₹566.83 Cr
Charges Breakdown by Lending Institutions
- Syndicate Bank : 292.53 Cr
- The Bank Of Nova Scotia : 140.00 Cr
- Icici Bank Limited : 100.00 Cr
- Export Import Bank Of India : 30.80 Cr
- Technology Development Board : 3.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Sep 2012 | Icici Bank Limited | ₹100.00 Cr | Satisfied |
| 30 Jun 2012 | Syndicate Bank | ₹100.00 Cr | Satisfied |
| 06 Sep 2005 | The Bank Of Nova Scotia | ₹140.00 Cr | Satisfied |
| 13 Dec 2004 | Syndicate Bank | ₹7.50 Cr | Satisfied |
| 09 Sep 2004 | Export Import Bank Of India | ₹10.00 Cr | Satisfied |
How Many Employees Work at Gland Pharma?
Gland Pharma has a workforce of 4769 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gland Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gland Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
